BNTX
USDBioNTech SE American Depositary Share
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$104.320
Kõrge
$107.000
Madal
$104.215
Maht
0.13M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
25.2B
Tööstusharu
Biotehnoloogia
Riik
Germany
Kauplemisstatistika
Keskmine maht
0.85M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140
HC Wainwright & Co. analyst Robert Burns maintains BioNTech with a Buy and raises the price target from $136 to $140.
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging
BioNTech to Host Innovation Series R&D Day on November 11, 2025
MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120
JP Morgan analyst Jessica Fye maintains BioNTech with a Neutral and lowers the price target from $121 to $120.
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.